← Patent-cliff monitor small molecule XHANCE FLUTICASONE PROPIONATE
Loss of exclusivity February 2036 latest FDA-listed patent expiry
Drug detail Brand name XHANCE Active ingredient FLUTICASONE PROPIONATE Strength 0.093MG/SPRAY Dosage form SPRAY, METERED Route NASAL Modality Small molecule FDA approval September 2017 Marketing status RX
Listed patents Patent Expires Type 11554229 February 2036 use U-2133 12616806 February 2036 use U-4525 12083270 April 2031 use U-2133
Regulatory exclusivity Code Expires I-940 March 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.